Stability of hepatitis B surface antigen over time: Implications for studies using stored sera

Journal of Medical Virology

Volumn 83, Issue 11, 2011, Pages 1900-1904

  Fung, James ^a   Lai, Ching Lung ^a   Young, John ^a   Wong, Danny Ka Ho ^a   Yuen, John ^a   Seto, Wai Kay ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic hepatitis B; HBsAg; Quantitative

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS;

ADULT; AGED; FEMALE; FREEZING; HEPATITIS B SURFACE ANTIGENS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN STABILITY; SPECIMEN HANDLING; TIME FACTORS;

HEPATITIS B VIRUS;

EID: 80052738299     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22171     Document Type: Article

References (25)

1. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. 2009. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49: 1141-1150.
2. Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S. 2010. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 48: 22-26.
3. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. 2007. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 5: 1462-1468.
4. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. 2010. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52: 1232-1241.
5. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, Lu SN. 2004. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol 16: 1213-1218.
6. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. 2006a. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
7. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. 2006b. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 101: 1797-1803.
8. Chen J, Wang Z, Guo Y, Peng J, Sun J, Ahmed CS, Zhou Y, Hou J. 2009. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral Res 81: 88-91.
9. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, Iinuma K, Mushahwar IK. 2004. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 115: 217-222.
10. Fung J, Lai CL, Young J, Wong DKH, Yuen J, Seto WK, Yuen MF. 2011. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol. DOI: 10.1038/ajg.2011.253.
11. Jung YK, Kim JH, Lee YS, Lee HJ, Yoon E, Jung ES, Hong SK, Joo MK, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. 2010. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 44: 653-657.
12. Krajden M, Comanor L, Rifkin O, Grigoriew A, Minor JM, Kapke GF. 1998. Assessment of hepatitis B virus DNA stability in serum by the Chiron Quantiplex branched-DNA assay. J Clin Microbiol 36: 382-386.
13. Krajden M, Minor JM, Rifkin O, Comanor L. 1999. Effect of multiple freeze-thaw cycles on hepatitis B virus DNA and hepatitis C virus RNA quantification as measured with branched-DNA technology. J Clin Microbiol 37: 1683-1686.
14. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. 2004. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: Implications for future HBV screening policy. Transfusion 44: 1332-1339.
15. Lai CL, Ratziu V, Yuen MF, Poynard T. 2003. Viral hepatitis B. Lancet 362: 2089-2094.
16. Lee W. 1997. Hepatitis B virus infection. N Engl J Med 337: 1733-1745.
17. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. 2008. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 3: 263-283.
18. Liver EAftSot. 2009. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009: 227-242.
19. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: Update 2009. Hepatology 50: 661-662.
20. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. 2007. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: A clue from serum HBsAg levels. Antivir Ther 12: 73-82.
21. Ozdil B, Cosar AM, Akkiz H, Sandikci MU, Kece C. 2009. Negative correlation between viral load and HBsAg levels in chronic HBV-infected patients. Arch Virol 154: 1451-1455.
22. Sanlidag T, Akcali S, Ozbakkaloglu B. 2005. Serum hepatitis B DNA: Stability in relation to multiple freeze-thaw procedures. J Virol Methods 123: 49-52.
23. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. 2009. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 46: 117-123.
24. Van Bommel F, Bock F, Hensel-Wiegel K, Schlosser B, Biermer M, Fulop B, Weich V, Schott E, Wiedenmann B, Berg T. 2009. Kinetics of HBsAg levels in patients with chronic hepatitis B virus (HBV) infection during up to 4 years of treatment with acyclic nucleotide analogues. Hepatology 50: 522A.
25. Wursthorn K, Jung M, Manns M, Lopez P, Wedemeyer H, Naumov N. 2009. Different kinetics of serum HBsAg decline in HBeAg-positive vs HBeAg-negative patients during 3 years of telbivudine treatment in chronic hepatitis B. Hepatology 50: 536A.